Primary malignant fibrous histiocytoma of the kidney: report of a case and literature review

Böbreğin primer malign fibröz histiositomu: olgu sunumu ve literatür özetı

Çağatay Göğüş¹, Mehmet İlker Gökce¹, Evren Süer¹, Özden Tulunay², Mut Şafak¹

ABSTRACT

We report a 44-year-old woman with a malignant fibrous histiocytoma (MFH) of the kidney. Primary renal MFH is an extremely rare tumor with a poor prognosis. Renal MFH is differentiated from renal cell carcinoma, renal sarcoma, and sarcomatoid renal tumors only by histological and immunohistochemical studies. Because the therapeutic options for MFH are different, its early diagnosis is imperative.

Key words: Immunohistochemistry; malignant fibrous histiocytoma; renal cell cancer.

ÖZET


Anahtar sözcüklər: Immunohistokimya; malign fibröz histiositom; renal hücreli kanser

Introduction

Renal sarcoma is uncommon and constitutes only 1% to 3% of all malignant renal tumors. Malignant fibrous histiocytoma (MFH) is an unusual type of renal sarcoma and is believed to arise from primitive mesenchymal cells that demonstrate both histiocytic and fibroblastic differentiation. Retroperitoneal primary MFH with renal involvement is not uncommon, but renal MFH is rare; approximately 55 cases have been reported in the literature.[1]

We present a new case of renal MFH diagnosed using a wide range of immunohistochemical studies.

Case Report

A 44-year-old woman presented with a 6-month history of left flank pain and abdominal discomfort. A physical examination confirmed the presence of a large mass in the left hypochondrium. Laboratory tests showed an elevated sedimentation rate and anemia, but chest X-rays were normal. Ultrasonographic imaging revealed a 12x10x10 cm solid tumor spreading into perirenal fat in the lower-mid portion of the left kidney. Computer tomography (CT) confirmed the tumor with suspected invasion of the sigmoid colon. However, no distant organ metastases were found.

The patient underwent left radical nephrectomy by a transperitoneal approach. Partial left colon resection was also performed, with a tumor-free surgical margin on frozen sections. Three courses of polychemotherapy with Adriblastina, Holoxan, Uromitexan, and radiotherapy were performed. However, she died as a result of the disease within the first postoperative year. Informed consent was obtained from the patient regarding sharing her clinical data for scientific purposes.

Pathological features

The kidney had a nodular surface and demonstrated a hemorrhagic tissue defect. Kidney
tissue sections demonstrated that tumor had replaced 14x14x9 cm of the renal tissue.

Although CT appeared to demonstrate that the tumor involved the mesentery of the sigmoid colon, the resected left colon segment was free of tumor. Mesenteric lymph nodes dissected from the colon demonstrated reactive changes.

Five months after hospital discharge, the patient was readmitted with tumor recurrence and omental metastases. A jejunal lesion was documented by ultrasound, and multiple metastases were observed within the mesenteric tissues. Eight months after the initial operation, a left omental resection was performed, and the omental tissues were observed to be widely occupied by a tumor with histology similar to the primary tumor.

Histologically, the kidney was widely occupied by a pleomorphic sarcomatous tumor. Microscopic examination showed that the tumor was composed of elongated spindle cells displaying a patchy and faint storiform pattern invading the renal tissue (b) (×50). Areas with a high degree of cellular pleomorphism composed of rounded, polygonal, and irregularly shaped histiocyte-like cells, often with very bizarre multinucleated giant cells with abundant eosinophilic cytoplasm were interspersed (Figure 2). Tumor cells penetrated the capsule into the perinephric fat.

Figure 1. The renal parenchyma is widely occupied by a pleomorphic sarcomatous tumor composed of elongated spindle cells with marked pleomorphism and multinucleated pleomorphic giant cells (a–c) (×10, ×10, ×10). Tumor embedded in collagenous stroma, leaving only scattered cells within a large collagenous background (×10)

Figure 2. Histology of the tumor, HE. Spindle and histiocytic cells (a), including multinucleated pleomorphic giant cells with bizarre nuclei (c) (×10, ×25). Elongated plump spindle cells arranged in short fascicles displaying a patchy and faint storiform pattern invading the renal tissue (b) (×50). Areas with a high degree of cellular pleomorphism composed of rounded, polygonal, and irregularly shaped histiocyte-like cells, often with very bizarre multinucleated giant cells with abundant eosinophilic cytoplasm (d) (×100)

Figure 3. Immunohistochemistry of the tumor, Peroxidase. CD68 expression in spindle and histiocytic cells (a, c) (×25, ×25) and giant cells (b, d) (×25, ×50). Strong and diffuse vimentin positivity (e) (×25)

Immunochemistry

Immunohistochemical (IHC) analysis of the tumor was performed, as shown in Table 1. The primary tumor cells were diffusely positive for CD10, vimentin (VIM) and CD68 (Figure 3). Stains for α1-antitrypsin and α1-antichymotrypsin were strongly and moderately positive, respectively, in the tumor cells, but stains for pan cytokeratin (pan CK), epithelial membrane antigen (EMA), smooth-muscle actin (SMA), S-100 protein (S-100) and desmin were negative. Additional IHC analyses were performed for the metastatic intestinal and omental lesions,
and they demonstrated that those tumors were also negative for panCK, EMA, SMA, S100, desmin, NSE, CD34, HMB45, and C-Kit and were strongly positive for VIM and CD68. The histological and IHC features were those of an MFH, and the histopathological diagnosis was storiform-pleomorphic MFH arising from the kidney.

**Discussion**

Primary sarcomas of the kidney are rare, accounting for only 1% to 3% of malignant renal tumors.\[2\] Approximately 12% to 14% of MFHs occur in the retroperitoneum or kidneys. Retroperitoneal MFH may also involve the kidney by local extension.\[1\] The mainstay of treatment is surgery, and adjuvant chemotherapy has also been suggested to improve survival.\[3\] MFHs arising from the renal parenchyma or renal capsule represent less than 6% of renal sarcomas.\[4-11\] The most frequent presenting symptoms are a palpable abdominal mass, fever, fatigue, weight loss, and gastrointestinal problems.\[12\] These symptoms are non-specific and usually appear late. Therefore, early diagnosis is difficult. A correct preoperative diagnosis was not made in any of the reports in the literature. Symptoms, a physical examination, and imaging are not sufficient for the clinical diagnosis of renal MFH, and the diagnosis can only be made histopathologically. The tumor is thought to arise from the system of Gerota’s fascia/renal capsule and must be differentiated from other more frequent renal cell carcinomas because it has a poor prognosis and requires additional treatment. Primary renal MFH is a tumor of the middle aged and elderly, with equal sex distribution, and most likely due to the small sample size, a predilection for the left kidney.\[13\] The symptoms appear late and are non-specific; therefore, early diagnosis is difficult.\[14\] In most cases, MFH presents with less parenchymal involvement in imaging studies and more frequently with normal urine compared to renal cell carcinoma.\[15\]

Malignant fibrous histiocytoma must be differentiated from other sarcomas, sarcomatoid carcinoma, and renal cell carcinoma.\[13,16,17\] Because most renal MFHs arise from the capsule, intracavitary progression and consecutive hematuria are rare.\[13,18,19\] Symptoms, a physical examination, and imaging are insufficient for differentiating MFH from other renal tumors, and histopathology is essential for its differentiation.\[18-21\] MFH is a common type of soft tissue sarcoma that was initially described four decades ago, and it has been shown to have the characteristics of both mesenchymal cells and mononuclear phagocytes.\[22-24\] The most common renal sarcomas are characterized by typical immunophenotypes that include negativity for CD68.\[20\] MFH is also positive for vimentin and α-1-antitrypsin, but these are less specific. Unlike sarcomatoid carcinoma, MFH lacks immunoreactivity for epithelial markers.\[13,25\]

<table>
<thead>
<tr>
<th><strong>ANTIBODY</strong></th>
<th><strong>Source</strong></th>
<th><strong>Dilution</strong></th>
<th><strong>Reactivity</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pan cytokeratin (panCK)[^a^]\</td>
<td>Novocastra</td>
<td>1:50</td>
<td>-</td>
</tr>
<tr>
<td>CD10[^b^]\</td>
<td>Novocastra</td>
<td>1:50</td>
<td>+</td>
</tr>
<tr>
<td>Epithelial membrane antigen (EMA)[^a^]\</td>
<td>Novocastra</td>
<td>1:300</td>
<td>-</td>
</tr>
<tr>
<td>Vimentin (VIM)[^b^]\</td>
<td>Neomarkers</td>
<td>1:200</td>
<td>+</td>
</tr>
<tr>
<td>Smooth-muscle actin (SMA)[^b^]\</td>
<td>Neomarkers</td>
<td>1:300</td>
<td>-</td>
</tr>
<tr>
<td>Desmin[^a^]\</td>
<td>Novocastra</td>
<td>1:50</td>
<td>-</td>
</tr>
<tr>
<td>Myoglobin[^b^]\</td>
<td>Immunon</td>
<td>1:600</td>
<td>-</td>
</tr>
<tr>
<td>S-100 protein (S-100)[^a^]\</td>
<td>Zymed</td>
<td>1:50</td>
<td>-</td>
</tr>
<tr>
<td>NSE[^d^]\</td>
<td>Neomarkers</td>
<td>1:25</td>
<td>-</td>
</tr>
<tr>
<td>CD68[^a^]\</td>
<td>Dako</td>
<td>1:75</td>
<td>+</td>
</tr>
<tr>
<td>HMB45[^b^]\</td>
<td>Dako</td>
<td>1:50</td>
<td>-</td>
</tr>
<tr>
<td>CD34[^b^]\</td>
<td>Neomarkers</td>
<td>1:30</td>
<td>-</td>
</tr>
<tr>
<td>C-kit[^b^]\</td>
<td>Novocastra</td>
<td>1:50</td>
<td>-</td>
</tr>
</tbody>
</table>

\[^a^]\ Sections were preheated with 0.1% trypsin for 3 min at 37°C.
\[^b^]\ Sections were preheated in a conventional pressure cooker for 90 seconds in a citrate buffer solution
\[^c^]\ Sections were preheated in a conventional pressure cooker for 90 seconds in an EDTA solution
\[^d^]\ No pretreatment was performed
The treatment of MFH is radical surgery. The role of adjuvant radiotherapy is questionable and offers little, if any, benefit. Only early radical surgery and postoperative polychemotherapy can achieve success. If local infiltration or distant metastases are present, treatment with polychemotherapy may be indicated, although the effectiveness is questionable and the response rate is only 33%. The overall prognosis is poor, and the 5-year survival rate is less than 14%. The present case demonstrated recurrence and metastases postoperatively within five and eight months, respectively, and despite polychemotherapy, the patient died of disease within the first postoperative year.

Conflict of Interest
No conflict of interest was declared by the authors.

Peer-review: Externally peer-reviewed.

Informed Consent: Written informed consent was obtained from patients who participated in this case.

Author Contributions
Concept - Ç.G., M.Ş.; Design - M.I.G., E.S., Ö.T.; Supervision - Ç.G., M.Ş.; Funding - M.I.G., E.S.; Materials - M.I.G., E.S., Ö.T.; Data Collection and/or Processing - M.I.G., E.S., Ö.T.; Analysis and/or Interpretation - Ç.G., E.S., Ö.T.; Literature Review - M.I.G., E.S., Ö.T.

References